Ignite Creation Date:
2024-05-06 @ 7:04 AM
Last Modification Date:
2024-10-26 @ 11:44 AM
Study NCT ID:
NCT02466568
Status:
WITHDRAWN
Last Update Posted:
2019-09-09
First Post:
2015-06-05
Brief Title:
Study of Nivolumab in Combination With GMCD40L Vaccine in Adenocarcinoma of the Lung
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A Randomized Phase III Study of Nivolumab in Combination With GMCD40L Vaccine in Adenocarcinoma of the Lung
Status:
WITHDRAWN
Status Verified Date:
2019-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Funding unavailable
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to find out what effects good and bad a tumor vaccine GMCD40L used in combination with Nivolumab will have on participants and their cancer Another purpose of the study is to find out the maximum tolerated dose of nivolumab in combination with GMCD40L vaccine Investigators also want to find out if the combination of GMCD40L and nivolumab can boost the immune system of participants like you and how their immune system reacts both before and after the treatment
Detailed Description:
This study has two parts and participants may be involved in either Phase I part or Phase II
Phase I Investigators plan to enroll participants in cohorts of 6 and monitor side effects over a 21 day period to determine the maximum tolerated dose MTD of nivolumab which will be given in combination with GMCD40L This is being done since this study involves a combination of treatments that have not been studied in humans before and to find the best dose for the Phase II part of the study
Phase II Investigators plan to compare any clinical benefit in the participants who receive the combination of GMCD40L vaccine with nivolumab to participants that receive only nivolumab
Phase I Investigators plan to enroll participants in cohorts of 6 and monitor side effects over a 21 day period to determine the maximum tolerated dose MTD of nivolumab which will be given in combination with GMCD40L This is being done since this study involves a combination of treatments that have not been studied in humans before and to find the best dose for the Phase II part of the study
Phase II Investigators plan to compare any clinical benefit in the participants who receive the combination of GMCD40L vaccine with nivolumab to participants that receive only nivolumab
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1504-1392 | OTHER | NIH Office of Biotechnology Activities OBA | None |